16432380Oikonomou I, Shen BInflammatory bowel diseasesBiological Products; Crohn Disease; Polyethylene GlycolsAdolescent; Adult; Antibodies, Monoclonal, Humanized; Certolizumab Pegol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Forecasting; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Prospective Studies; Risk Assessment; Treatment OutcomeAre we moving forward in the biological treatment of Crohn's disease? Time will tell. Inflamm Bowel Dis. 2006 Feb; 12(2):147-9.Inflamm Bowel Dis2006-02-01T00:00:002006Are we moving forward in the biological treatment of Crohn's disease? Time will tell.Faculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD004311Procedures1165030.892567Double-Blind Methodtrue1Associate ProfessorAssociate ProfessorIoannisOikonomouIoannis Oikonomou350053Oikonomou, IoannisAssociate ProfessorAuthorship 3343810.2841660.2841661authors10.2520has subject areaD016896Concepts & Ideas36434750.519213Treatment OutcomeD011092Chemicals & Drugs22550.948951Polyethylene GlycolsD001688Chemicals & Drugs18400.918448Biological ProductsD000293Living Beings36322740.634821AdolescentD003424Disorders15460.965593Crohn DiseaseD011446Concepts & IdeasProcedures28318080.67251Prospective Studies5Associate ProfessorD004305Concepts & Ideas1464380.910734Dose-Response Relationship, DrugD061067Chemicals & Drugs411130.922308Antibodies, Monoclonal, HumanizedD005544Concepts & IdeasOccupations781170.951296ForecastingD008875Concepts & IdeasLiving Beings48398170.373681Middle AgedD018570Concepts & IdeasProcedures2186780.786868Risk AssessmentD005500Procedures28018280.683531Follow-Up StudiesD000328Living Beings51685930.393483AdultD008297Physiology564156270.299065MaleD005260Physiology579162020.293532FemaleD007140Chemicals & Drugs330.997478Immunoglobulin Fab FragmentsInternal MedicineRush University, Rush Medical CollegeD004334Concepts & Ideas842230.947666Drug Administration ScheduleD006801Living Beings643293340.211949HumansD000068582220.999126Certolizumab Pegol